Join us in Rome for the 31st ESGCT congress, which will take place from October 22nd to October 25th. ESGCT’s Annual Congress brings together scientists working in cell and gene therapy throughout Europe and beyond.
Translating cell and gene therapies from early stages to the clinic has become increasingly complex for biotech and pharma companies. There is a need to access expertise, data, and scientific insights to bring the right patient to the right treatment at the right time.
Engage with our team of experts who will provide customized solutions to challenges like:
How to deal with highly complex trials;
Flexibility in developing and validating customized assays;
Multifaceted logistics management specialized for cell & gene therapies;
Evolving regulatory guidance and standards;
Ensuring transparency, oversight, and swift turn-around times;
Accessibility to scientific expertise and a comprehensive off-the-shelf and customizable assay offering. Read more here
Cerba Research will host a round table on Advancing AAV gene therapy trials: addressing immunogenicity and safety. Make sure to engage with our team to obtain the round table report after the ESGCT congress.
In addition, we will present two poster presentations:
For more information on the ESGCT conference, please visit the website here.
Meet the team
Karthikeyan Devaraju
PhD, Senior Scientist
Karthikeyan Devaraju has over 15 years’ experience in the regenerative medicine and advanced therapies (diverse cell and gene therapies). His expertise spans stem cells, cell fate engineering, gene delivery systems, product development and both process and analytical development / optimization using diverse technology platforms. He received his PhD in Stem Cells and Neurology from Lund University. He has held various scientific positions in academic research institutions, bio-pharma and CDMOs.
Dorota Talady
MSc, Business Development
Dorota Talady has over 8 years of experience in development and commercialization of specialized virology assays to support advanced therapies and vaccines. She joined Cerba Research as an R&D scientist, overseeing development and validation activities in virology portfolio. Currently responsible for business development.
Ivo Ploemen
PhD, Business Development and Strategy
Ivo Ploemen has over 15 years of experience in the life science industry. He received a PhD in Medical Microbiology from the Radboud University and an executive MBA from Tias School for Business and Society. Ivo has held various roles with a key focus on Strategy in both start-ups, CRO’s and CDMO’s.
Download our Cell and Gene Therapy publications below
Cerba Research is a leading specialty laboratory services provider across all clinical development phases, to pharmaceutical, biotechnology, medical device, government, and public health organizations. It combines the deep scientific expertise of specialist services with the capacity and breadth of a global central laboratory network. Cerba Research develops innovative solutions to unique challenges in research and drives operational agility at scale for multiple therapeutic areas, with world recognized expertise in virology, oncology and cell & gene therapy. It is part of the Cerba HealthCare Group with 15,000 employees on five continents, driven to advance health diagnosis.
